Clinical Trial Update: Nemtabrutinib, Bortezomib, and Rituximab for WM [Phase 2]

View source ↗

Summary

Phase 2 clinical trial at Seoul National University Hospital evaluating nemtabrutinib in combination with bortezomib and rituximab for Waldenström macroglobulin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Bortezomib (bortezomib)
• Nemtabrutinib (nemtabrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: NOT_YET_RECRUITING